Astellas v. Sandoz, Lupin & Zydus: Federal Circuit Vacates Myrbetriq® Patent Ruling
Astellas Pharma and its affiliates appealed an infringement decision covering US10842780B2 — the patent underpinning Myrbetriq® extended-release tablets (25 mg and 50 mg) — against six generic challengers including Sandoz, Lupin, and Zydus. The Federal Circuit vacated and remanded the lower court’s decision after 460 days, returning the dispute for further proceedings without affirming or reversing on the merits.
Federal Circuit wipes the slate on Myrbetriq® ANDA patent battle
Astellas Pharma, Inc., Astellas Pharma Global Development, Inc., and Astellas Ireland Co., Ltd. brought this infringement action to protect US10842780B2, the key patent covering Myrbetriq® extended-release tablets in the 25 mg and 50 mg strengths. The defendants — Sandoz, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., Zydus Lifesciences Ltd., Zydus Pharmaceuticals (USA) Inc., and Lek Pharmaceuticals D.D. — are generic manufacturers whose ANDA filings triggered the Hatch-Waxman litigation. The appeal was filed at the Court of Appeals for the Federal Circuit on 16 June 2023.
On 18 September 2024, the Federal Circuit issued a vacatur and remand, nullifying the lower court’s decision and returning the case for further adjudication. A vacatur does not represent a victory for either party on the merits: the lower court’s factual findings and legal conclusions are set aside, obligating the district court to reconsider the dispute in light of the appellate court’s guidance. Astellas retains its patent and its right to enforce; the generic defendants have not been cleared to market.
The 460-day appellate timeline is broadly consistent with contested Federal Circuit ANDA appeals. Because the Federal Circuit’s opinion drove a remand rather than a final resolution, the commercial uncertainty over generic entry into the mirabegron market persists. The precise legal basis for vacatur — whether grounded in claim construction, obviousness, or another doctrine — is not fully discernible from the public record alone, and the district court’s reconsidered decision will determine the ultimate enforceability of US10842780B2 against this group of challengers.
Filing to Vacated and Remanded in 460 days
460 days from filing to Federal Circuit disposition — above median for ANDA-related appeals
Federal Circuit vacates: what the remand means for both parties
Vacatur nullifies the lower court ruling — nothing is final yet
When the Federal Circuit vacates a district court decision, it erases that ruling from the record rather than simply correcting it. The lower court must reconsider the case — typically under fresh instructions from the appellate panel — meaning neither side can rely on the prior outcome. Vacatur is distinct from reversal: the Federal Circuit has not ruled in favour of either Astellas or the generic defendants; it has determined only that the original decision cannot stand as issued.
Lower decision set asideAstellas retains patent rights but enforceability remains unresolved
US10842780B2 survives this appeal intact — the vacatur does not invalidate the patent or find non-infringement. Astellas and its affiliates return to the district court with the opportunity to re-litigate the claims. However, the absence of a favourable final judgment means Astellas cannot yet rely on this litigation to block generic entry with certainty; a 30-month stay under Hatch-Waxman may still govern the commercial timeline depending on the remand proceedings.
Patent intact, litigation continuesGeneric defendants face renewed district court scrutiny
Sandoz, Lupin, Zydus, and Lek did not obtain the clearance they sought on appeal. The vacatur removes any district court ruling that may have favoured them, and they must now defend their ANDA positions again before the remand court. The Federal Circuit’s guidance will constrain or reframe the issues, which could narrow defences previously available. Until the remand is resolved, commercial launch of generic mirabegron ER carries material infringement risk.
Generic launch risk persistsMirabegron ER market exclusivity window stays open for now
Myrbetriq® (mirabegron) is a significant overactive bladder franchise for Astellas. The vacatur-and-remand outcome extends the period of uncertainty for generic market entry, which typically supports continued brand revenue while remand proceedings unfold. For investors and competitors tracking the mirabegron space, this outcome suggests the district court proceedings will be the next critical inflection point — and the Federal Circuit’s reasoning, once published, may reshape the claim construction or validity landscape for the broader beta-3 adrenergic agonist patent portfolio.
Brand exclusivity extended near-termFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Astellas Pharma, Inc. | Company | Pharmaceutical innovator — holder of US10842780B2 covering Myrbetriq® mirabegron ER tabletsSearch in Eureka ↗ |
| Co-Plaintiff | Astellas Pharma Global Development, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Astellas Ireland Co., Ltd. | Company | Search in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | Generic manufacturers (Sandoz, Lupin, Zydus, Lek) seeking ANDA approval for mirabegron ER tabletsSearch in Eureka ↗ |
| Co-Defendant | Zydus Lifesciences Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Zydus Pharmaceuticals (USA), Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Lek Pharmaceuticals, D.D. | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Andrew LyonsBerg | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Seidell | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jason Albert Leonard | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Paul Whitfield Hughes, III | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Simon Roberts | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English, LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McDermott Will & Emery LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Deanne M. Mazzochi | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Kevin Patrick Burke | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Rachel Pernic Waldron | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | William A. Rakoczy | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Rakoczy, Molino, Mazzochi, Siwik LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s disposition of ‘VACATED AND REMANDED’ carries precise legal weight: the lower court’s judgment is nullified in its entirety and the case is returned for reconsideration consistent with the appellate court’s opinion. At the Federal Circuit, vacatur typically follows a finding that the district court applied an incorrect legal standard or made a reversible error on a dispositive issue — such as claim construction or the obviousness analysis — without the appellate record being sufficient for the Federal Circuit to render a final judgment itself. Neither Astellas nor the generic defendants emerge with a merits determination in their favour. The enforceability of US10842780B2 against these ANDA filers remains live and contested.
US10842780B2 — Myrbetriq® mirabegron extended-release tablet formulation
US10842780B2 (application number US15/432854) protects Myrbetriq® extended-release tablets containing mirabegron — a beta-3 adrenergic agonist used to treat overactive bladder. The patent covers the specific formulation of the 25 mg and 50 mg dosage strengths that deliver controlled drug release. As a pharmaceutical composition or formulation patent, it is enforceable against any ANDA filer seeking to market a bioequivalent product without a successful invalidity or non-infringement finding.
Myrbetriq® is one of Astellas’s flagship branded products, and US10842780B2 is a critical line of defence against generic erosion in the overactive bladder treatment market. The involvement of six generic defendants — spanning Sandoz (a Novartis subsidiary), Lupin, Zydus, and Lek — signals that multiple major generics view a path to market as commercially viable. The Federal Circuit’s vacatur decision, and the eventual remand outcome, will determine whether this patent provides durable exclusivity or is vulnerable to challenge. Companies developing competing beta-3 adrenergic agonist formulations should monitor the remand proceedings closely.
Should your team run an FTO analysis against US10842780B2?
Any pharmaceutical or generics company developing extended-release mirabegron formulations — or closely related beta-3 adrenergic agonist products — should treat US10842780B2 as an active enforcement risk. The Federal Circuit’s vacatur does not invalidate or narrow the patent’s claims; the patent remains in force pending the district court’s remand decision. Product teams planning ANDA filings or NDA submissions in the overactive bladder space should assess whether their formulation falls within the claim scope of this patent before committing to development timelines.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map the claim landscape of US10842780B2 against candidate formulations in minutes — surfacing overlapping claim language, prosecution history estoppel, and related family members across jurisdictions. With litigation actively ongoing on remand, a structured FTO analysis is a prerequisite for informed go/no-go decisions in extended-release mirabegron product development.
Run a freedom-to-operate analysis on US10842780B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit ANDA patent appeals in pharmaceutical formulation IP
Explore Federal Circuit appeals involving Hatch-Waxman ANDA infringement actions over extended-release pharmaceutical formulation patents, including comparable vacatur and remand outcomes.
What this case signals for the pharmaceutical ANDA patent landscape
A Federal Circuit vacatur in a multi-defendant ANDA case prolongs uncertainty for both innovators and generics — with distinct strategic consequences.
Vacatur-and-remand is a high-stakes reset, not a win for either side
IP teams should treat a Federal Circuit vacatur as a signal that the lower court’s analysis was procedurally or substantively flawed at a level the appellate panel could not simply correct. For brand pharmaceutical holders, it preserves the patent but restarts the clock. For generics, it removes any favourable district court ruling without providing affirmative clearance. Both sides face renewed litigation cost and uncertainty.
Multi-defendant ANDA structure amplifies remand complexity
With six defendants across the Sandoz, Lupin, Zydus, and Lek entities, the remand proceedings for Astellas involve coordinating positions across multiple ANDA filers simultaneously. Differences in each defendant’s ANDA product specification or invalidity arguments may produce divergent outcomes at the district court level. Patent counsel monitoring this remand should track each defendant’s posture independently.
Astellas v Sandoz — key questions answered
The vacatur nullifies the district court’s prior decision but does not invalidate US10842780B2. The patent remains in force and the case is remanded for further proceedings. Astellas retains its right to enforce the patent; the generic defendants have not received judicial clearance to market mirabegron ER tablets.
The defendants are Sandoz Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Zydus Lifesciences Ltd., Zydus Pharmaceuticals (USA) Inc., and Lek Pharmaceuticals D.D. The product at issue is Myrbetriq® extended-release tablets containing mirabegron in 25 mg and 50 mg strengths, protected by US10842780B2.
A reversal means the Federal Circuit has decided the merits in the opposite direction to the lower court. A vacatur-and-remand means the lower court’s decision is nullified and the case is returned for reconsideration — typically because the district court applied an incorrect legal standard. Neither party receives a final merits ruling under a vacatur.
The vacatur itself does not directly alter Hatch-Waxman statutory timelines, but the absence of a final judgment means any 30-month stay implications must be re-evaluated based on the remand timeline. Generic defendants cannot launch at-risk without a final non-infringement or invalidity finding, making the remand proceedings commercially critical for both brand and generic parties.
Following the Federal Circuit’s vacatur and remand on 18 September 2024, the case is returned to the originating district court for further proceedings. The specific district court and remand docket are not identified in the Federal Circuit appellate record as reproduced here, but would be the court that issued the original judgment under appeal.
PatSnap Eureka searches patents and litigation data to answer instantly.